Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers

BACKGROUND: Tislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fcγ receptors. It has been used to treat several solid tumors. However, its efficacy and toxicity, and the predictive and prognostic value of baseline hematological parameters in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiaojing, Gu, Haifeng, Cao, Xinping, Pan, Baoyue, Xiang, Huiling, Ju, Mingxiu, Xu, Shijie, Zheng, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975598/
https://www.ncbi.nlm.nih.gov/pubmed/36875089
http://dx.doi.org/10.3389/fimmu.2023.1113369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975598/
https://www.ncbi.nlm.nih.gov/pubmed/36875089
http://dx.doi.org/10.3389/fimmu.2023.1113369

Ejemplares similares